CHICAGO, IL—Reports of device embolization during the limited market rollout of the next-generation Watchman FLX left atrial appendage closure device in Europe have caused manufacturer Boston ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

(RTTNews) - Boston Scientific (BSX) said that 24-month results from the PINNACLE FLX clinical trial demonstrated the safety and performance of WATCHMAN FLX left atrial appendage closure device for ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

Left atrial appendage (LAA) closure with the new-generation Watchman FLX device (Boston Scientific) provides a high rate of effective closure with few early adverse events, according to results of ...

Boston Scientific (BSX) announced an update on their ongoing clinical study.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

(RTTNews) - Medical technology company Boston Scientific Corp. (BSX) announced Tuesday that it has received U.S. Food and Drug Administration approval for expanded labeling of WATCHMAN FLX Left Atrial ...

The WATCHMAN FLX Pro team (pictured here) has successfully completed 159 WATCHMAN procedures, and will now only use the updated WATCHMAN FLX Pro Device moving forward. (Courtesy Photo) Medical Center ...